Vedanta Biosciences Stock

vedantabio.comHealthcareFounded: 1900Funding to Date: $211.6MM

Vedanta Biosciences is a biotechnology company focused on developing a potential new category of oral therapies based on rationally-defined consortia of bacteria derived from the human microbiome.

Register for Details

For more details on financing and valuation for Vedanta Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Vedanta Biosciences.

Register Today

Team

Management Team

Bernat Olle Ph.D
Co-Founder, Chief Executive Officer & Board Member
Ruslan Medzhitov Ph.D
Chairman of Scientific Advisory Board & Scientific Co-Founder
Kevin Coveney
Senior Vice President, Finance
Dan Littman Ph.D
Scientific Co-Founder & Scientific Advisory Board Member
Bruce Roberts Ph.D
Chief Scientific Officer
Erik Spek Ph.D
Senior Vice President and Head, Legal Affairs & Intellectual Property
Lou Vaickus MD
Chief Medical Officer
Alexander Rudensky Ph.D
Scientific Co-Founder & Scientific Advisory Board Member
Daniel Couto
Chief Technical Officer
Kenya Honda Ph.D
Scientific Co-Founder & Scientific Advisory Board Member
Debra Winslow
Vice President, Program Management & Operations Planning
B. Brett Finlay Ph.D
Scientific Co-Founder & Scientific Advisory Board Member

Board Members

Bernat Olle Ph.D
John LaMattina Ph.D
PureTech Health
Bharatt Chowrira Ph.D
PureTech Health
Kenya Honda Ph.D
Ruslan Medzhitov Ph.D
Bennett Shapiro MD
PureTech Health
Christopher Viehbacher
Susan Dillon Ph.D

Other companies like Vedanta Biosciences in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 

News

Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consorti